100
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Turner syndrome affects 25–50 per 100,000 females and can involve multiple organs through all stages of life, necessitating multidisciplinary approach to care. Previous guidelines have highlighted this, but numerous important advances have been noted recently. These advances cover all specialty fields involved in the care of girls and women with TS. This paper is based on an international effort that started with exploratory meetings in 2014 in both Europe and the USA, and culminated with a Consensus Meeting held in Cincinnati, Ohio, USA in July 2016. Prior to this meeting, five groups each addressed important areas in TS care: 1) diagnostic and genetic issues, 2) growth and development during childhood and adolescence, 3) congenital and acquired cardiovascular disease, 4) transition and adult care, and 5) other comorbidities and neurocognitive issues. These groups produced proposals for the present guidelines. Additionally, four pertinent questions were submitted for formal GRADE (Grading of Recommendations, Assessment, Development and Evaluation) evaluation with a separate systematic review of the literature. These four questions related to the efficacy and most optimal treatment of short stature, infertility, hypertension, and hormonal replacement therapy. The guidelines project was initiated by the European Society of Endocrinology and the Pediatric Endocrine Society, in collaboration with the European Society for Paediatric Endocrinology, the Endocrine Society, the European Society of Human Reproduction and Embryology, the American Heart Association, the Society for Endocrinology, and the European Society of Cardiology. The guideline has been formally endorsed by the European Society of Endocrinology, the Pediatric Endocrine Society, the European Society for Paediatric Endocrinology, the European Society of Human Reproduction and Embryology and the Endocrine Society. Advocacy groups appointed representatives who participated in pre-meeting discussions and in the consensus meeting.

          Related collections

          Most cited references569

          • Record: found
          • Abstract: found
          • Article: not found

          GRADE guidelines: 3. Rating the quality of evidence.

          This article introduces the approach of GRADE to rating quality of evidence. GRADE specifies four categories-high, moderate, low, and very low-that are applied to a body of evidence, not to individual studies. In the context of a systematic review, quality reflects our confidence that the estimates of the effect are correct. In the context of recommendations, quality reflects our confidence that the effect estimates are adequate to support a particular recommendation. Randomized trials begin as high-quality evidence, observational studies as low quality. "Quality" as used in GRADE means more than risk of bias and so may also be compromised by imprecision, inconsistency, indirectness of study results, and publication bias. In addition, several factors can increase our confidence in an estimate of effect. GRADE provides a systematic approach for considering and reporting each of these factors. GRADE separates the process of assessing quality of evidence from the process of making recommendations. Judgments about the strength of a recommendation depend on more than just the quality of evidence. Copyright © 2011 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Emerging adulthood: A theory of development from the late teens through the twenties.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

              The National High Blood Pressure Education Program presents the complete Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Like its predecessors, the purpose is to provide an evidence-based approach to the prevention and management of hypertension. The key messages of this report are these: in those older than age 50, systolic blood pressure (BP) of greater than 140 mm Hg is a more important cardiovascular disease (CVD) risk factor than diastolic BP; beginning at 115/75 mm Hg, CVD risk doubles for each increment of 20/10 mm Hg; those who are normotensive at 55 years of age will have a 90% lifetime risk of developing hypertension; prehypertensive individuals (systolic BP 120-139 mm Hg or diastolic BP 80-89 mm Hg) require health-promoting lifestyle modifications to prevent the progressive rise in blood pressure and CVD; for uncomplicated hypertension, thiazide diuretic should be used in drug treatment for most, either alone or combined with drugs from other classes; this report delineates specific high-risk conditions that are compelling indications for the use of other antihypertensive drug classes (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, calcium channel blockers); two or more antihypertensive medications will be required to achieve goal BP (<140/90 mm Hg, or <130/80 mm Hg) for patients with diabetes and chronic kidney disease; for patients whose BP is more than 20 mm Hg above the systolic BP goal or more than 10 mm Hg above the diastolic BP goal, initiation of therapy using two agents, one of which usually will be a thiazide diuretic, should be considered; regardless of therapy or care, hypertension will be controlled only if patients are motivated to stay on their treatment plan. Positive experiences, trust in the clinician, and empathy improve patient motivation and satisfaction. This report serves as a guide, and the committee continues to recognize that the responsible physician's judgment remains paramount.
                Bookmark

                Author and article information

                Journal
                European Journal of Endocrinology
                Bioscientifica
                0804-4643
                1479-683X
                September 2017
                September 2017
                September 2017
                September 2017
                : 177
                : 3
                : G1-G70
                Affiliations
                [1 ]1Departments of Endocrinology and Internal Medicine
                [2 ]2Departments of Molecular Medicine
                [3 ]3Departments of Cardiology, Aarhus University Hospital, Aarhus, Denmark
                [4 ]4Department of Women’s Health, University College London, London, UK
                [5 ]5Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands
                [6 ]6The Saban Research Institute, Children’s Hospital Los Angeles, Los Angeles, California, USA
                [7 ]7Rady Children’s Hospital, University of California, San Diego, California, USA
                [8 ]8Department of Pediatrics, Medical Genetics Unit, Mass General Hospital for Children, Boston, Massachusetts, USA
                [9 ]9Division of Endocrinology, Nemours Children’s Health System, Jacksonville, Florida, USA
                [10 ]10St Hubert’s Island, New South Wales, Australia
                [11 ]11Connecticut Children’s Medical Center, Hartford, Connecticut, USA
                [12 ]12Division of Psychology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA
                [13 ]13Department of Pediatric Endocrinology, Sophia Children’s Hospital, Rotterdam, The Netherlands
                [14 ]14Department of Pediatrics, Dordrecht, The Netherlands
                [15 ]15Department of Pediatrics, Doernbecher Children’s Hospital, Portland, Oregon, USA
                [16 ]16Väestöliitto Fertility Clinics, Helsinki, Finland
                [17 ]17Center for Rare Diseases, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
                [18 ]18Department of Pediatric Endocrinology, Radboud University Medical Center, Amalia Children’s Hospital, Nijmegen, The Netherlands
                [19 ]19Department of Pediatric Endocrinology, Children’s Hospital, University of Bonn, Bonn, Germany
                [20 ]20Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
                Article
                10.1530/EJE-17-0430
                28705803
                1416b1d3-fd4a-40ee-835e-3fea2e0ce72e
                © 2017

                Free to read

                History

                Comments

                Comment on this article